Most pathogens are rapidly cleared and the immune system becomes only transiently exposed to foreign antigens and inflammation. Such acute infections trigger the generation of large numbers of short-lived effector T cells and the formation of memory T cells [1] [2] [3] [4] [5] [6] [7] [8] . Following such infections, T cells typically co-express multiple cytokines (including tumour necrosis factor (TNF), interferon-γ (IFNγ) and interleukin-2) and cytotoxic effector molecules -a phenotype that is often referred to as polyfunctional 9 . A different outcome arises when infections become chronic and when viruses persist at high levels over long periods of time, as in HIV or human hepatitis C virus (HCV) infections. Such conditions induce T cells that lack the typical polyfunctional phenotype and that retain the expression of inhibitory receptors including programmed cell death protein 1 (PD1), lymphocyte activation gene 3 protein (LAG3), T cell immunoglobulin domain and mucin domain protein 3 (TIM3; also known as HVACR2) and CD160 . Similar phenotypes can be observed in T cells upon long-term exposure to tumour antigen [18] [19] [20] . The prevailing view is that: first, this phenotype marks severely functionally impaired, so-called exhausted T cells; second, that conventional memory T cells are not being formed in persisting infections 21 ; and third, that chronic infections cause a progressively weakening response and a shutdown of T cell-mediated immunity.
However, several clinical observations and experimental studies, including the therapeutic effects that are achieved by blocking PD1 signalling, are difficult to align with the concept that the T cell response only progressively deteriorates in chronic infections. Moreover, the term exhausted T cells implies that T cells acquire a non-functional state. However, we question whether the multifaceted expression pattern of receptors that inhibit T cell function have solely evolved to render T cells non-functional; such an outcome could be achieved by simply deleting antigen-specific T cells.
To resolve these discrepancies, we propose an extension of the current concept of T cell responses in chronic infections. Following the idea that chronic infections require an equilibrium between control of viral replication and the level of immune-mediated pathology caused by the persisting T cell responses 22 , we argue and provide evidence that functional adaptation, specialization and the acquisition of stable phenotypes, rather than simply exhaustion, are the driving forces that determine the T cell response in chronic infections. Thus, we postulate that the phenotype of exhausted T cells (referred to here as the chronic infection phenotype) reflects a finely tuned effector population that is optimized to fulfil a certain level of effector function and pathogen control without causing overwhelming immunopathology.
Origin of T cell exhaustion
The idea that chronic infections exhaust the T cell response was formulated following studies in mice that were persistently infected with the lymphocytic choriomeningitis virus (LCMV) docile strain. The ability to expand antigen-specific T cells from these mice in vitro declines over time, which led to the conclusion that a persisting infection exhausts or severely diminishes the pathogen-specific T cell response 13 . The introduction of tetramer technology and T cell receptor (TCR)-transgenic mice (P14), which generate CD8 + T cells specific for an LCMV-derived antigen (GP33), enabled more detailed studies and demonstrated a substantial loss of effector T cells in persisting LCMV infections 12, 14, 24 . Nonetheless, depending on the pathogen dose and the epitope being studied, a proportion of T cells bypasses deletion. In persisting infections with LCMV clone 13, T cells specific for the GP33 peptide were retained, whereas their NP396-specific counterparts were mostly deleted 12, 14 . The deletion is thought to result from a higher avidity of T cells for the NP396 peptide than for the GP33 peptide 23 . Moreover, the availability of LCMV strains which differ in their in vivo persistence (that is, acute WE or Armstrong strains and chronic clone 13 or docile strains) facilitated in-depth characterization of how the duration of infections that are caused by very similar pathogens influences T cell differentiation. These studies prompted the discovery of the abovementioned chronic infection phenotype 15, 24 , and established that the acquisition of this phenotype and the deletion of antigen-specific T cells are parallel or sequentially occurring events. Data showing that T cells that do not become deleted show a different phenotype, are difficult to re-expand in vitro and do not survive well following adoptive transfer into antigen-free hosts 25 sustained the concept that the residual T cells are non-functionala notion that intuitively goes along with the inability of the immune system to clear the virus. Over time, the use of the term T cell exhaustion has evolved, from referring to the presumed absence of antigen-specific T cells to predominantly being used to refer Abstract | Chronic viral infections and malignant tumours induce T cells that have a reduced ability to secrete effector cytokines and have upregulated expression of the inhibitory receptor PD1 (programmed cell death protein 1). These features have so far been considered to mark terminally differentiated 'exhausted' T cells. However, several recent clinical and experimental observations indicate that phenotypically exhausted T cells can still mediate a crucial level of pathogen or tumour control. In this Opinion article, we propose that the exhausted phenotype results from a differentiation process in which T cells stably adjust their effector capacity to the needs of chronic infection. We argue that this phenotype is optimized to cause minimal tissue damage while still mediating a critical level of pathogen control. In contrast to the presently held view of functional exhaustion, this new concept better reflects the pathophysiology and clinical manifestations of persisting infections, and it provides a rationale for emerging therapies that enhance T cell activity in chronic infection and cancer by blocking inhibitory receptors.
to T cells that have the chronic infection, exhausted phenotype. Although antigenspecific T cells in persisting infections clearly differ from their counterparts found in acute infections 24 , we focus our discussion on highlighting that these retained T cells are not an inert non-functional population and we favour the view that these retained T cells fulfil specialized functions. We are thereby also resolving the confusion that we refer to these T cells as being exhausted despite the evidence that we can re-activate their effector potential -for instance, by blocking PD1 signalling 26, 27 .
Evidence for maintained T cell function A characteristic feature of many persisting infections -including HIV, simian immuno deficiency virus (SIV) or HCV -is the appearance of virus variants that express mutated T cell epitopes. This phenomenon clearly requires ongoing antigen-specific CD8 + T cell function, but whether this viral variant selection can only be mediated by T cells with a normal effector phenotype or could involve T cells with an exhausted phenotype remains unclear. Nonetheless, the late appearance of mutant viruses in established chronic infection is a fundamental indicator of the long-term maintenance of functional T cell responses and highlights that exhausted T cell populations possibly contribute to selecting escape variants 28, 29 .
The association between the late emergence of escape mutations, a concomitant steep increase in viral load and disease progression to AIDS in HIV infections underlines the aforementioned considerations. Moreover, the number of HIV-specific T cells can increase following an interruption of antiretroviral therapy 30, 31 . Together with the evidence that HIV infections impair thymic output, this also reveals the retention of T cells in established chronic infections that can expand substantially 32, 33 . The demonstration that virus titres strongly increase following the depletion of CD8 + T cells in SIV-infected macaques [34] [35] [36] , and that protective immune responses can be elicited upon vaccinating SIV-infected rhesus macaques 37 , further underscores the strong effector capacity of CD8 + T cells in established chronic infections.
T cells with an exhausted phenotype can also be found following chronic antigen stimulation in tumours 19, [38] [39] [40] . Despite showing this phenotype, there is a clear positive correlation between the number of CD8 + tumour infiltrating lymphocytes (TILs) and a favourable clinical prognosis 41, 42 . Remarkably, 58 out of 60 studies highlight this correlation across patients with all of the major types of cancer [41] [42] [43] . Consistent with the studies showing immune control in the presence of phenotypically exhausted T cells, there is evidence that PD1 hi CD8 + T cells can express similar or even elevated levels of cytotoxic molecules compared to cells with a less pronounced exhausted phenotype 39, [44] [45] [46] [47] . The strongest evidence that exhausted T cells retain the ability to mount a potent effector response comes from the many studies in which strong antitumour or antiviral immunity could be restored by blocking the interaction between PD1 and PD1 ligand 1 (PDL1; also known as CD274), either alone or in combination with agents targeting other receptors 26, [48] [49] [50] [51] [52] [53] . This approach of antibody-mediated 'checkpoint blockade' is now increasingly used to treat patients with cancer and its impact on chronic infections in humans is being evaluated
. The efficacy of blocking PD1 signalling strongly implies that T cell function in chronic infections and cancer is not solely attenuated owing to an intrinsic loss of CD8 + T cell function, but rather it is because the function of these T cells is controlled by external regulatory mechanisms that involve PD1 signalling.
Another point to consider is that infections with LCMV clone 13, in which many features of exhausted T cells (including the relevance of PD1 expression) were established 15, 26 , show viral load kinetics that are
Box 1 | Clinical efficacy of checkpoint blockade in cancer and virus infection

Malignant diseases
The following list summarizes clinical trials in which significant therapeutic benefits were observed following the injection of monoclonal antibodies specific for inhibitory receptors (a therapy known as checkpoint blockade).
• Ipilimumab is a monoclonal antibody that blocks cytotoxic T lymphocyte antigen 4 (CTLA4) and improves disease outcome in patients with malignant melanoma 89 . This treatment was approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2011.
• Promising clinical results were obtained by blocking interactions between programmed cell death protein 1 (PD1) and PD1 ligand 1 (PDL1) in patients with melanoma, lung cancer and kidney cancer. Recent data suggest that this approach may be more efficient and less toxic than treatment with ipilimumab 81, [90] [91] [92] .
• Two Phase I clinical trials also suggested that combined PD1 and CTLA4 blockade could further improve the clinical responses (but with increased toxicity) in patients with melanoma [92] [93] [94] .
• According to the ClinicalTrials.gov website (data accurate as of August 2014), there are currently 320 ongoing trials in patients with cancer in which inhibitory receptors are being targeted: 216 trials with CTLA4-specific antibody; 65 trials with PD1-specific antibody; 33 trials with PDL1-specific antibody; one trial with PDL2-specific antibody; two trials with lymphocyte activation gene 3 protein (LAG3)-specific antibody; and three trials with killer cell immunoglobulin-like receptor (KIR)-specific antibodies. These ongoing trials are based on numerous basic research studies (reviewed in REFS 18, 95) .
Infectious diseases
The extent to which checkpoint blockade improves the clinical manifestation of persisting infections is currently being evaluated. Compared to extensive research in the setting of cancer, much less information is available concerning the efficacy of checkpoint blockade in chronic infections but several promising observations have been made, some of which are listed below. Nonetheless, more clinical studies are needed to confirm these early observations.
• A single dose of a PD1-specific blocking antibody decreased viral titres in 11-15% of patients with hepatitis C virus (HCV) infection. This included patients who were non-responders to the standard interferon therapy • In vitro studies showed that the cytotoxic ability of HIV-specific T cells could be rescued by blocking T cell immunoglobulin domain and mucin domain protein 3 (TIM3) 47 .
• Recently, a patient with melanoma was treated with CTLA4-specific antibody. Incidentally, his HCV infection was successfully controlled, despite the fact that he did not receive antiviral therapy 99 .
• Currently, there are four ongoing trials in which PD1-specific or PDL1-specific antibodies are being used to treat patients with chronic infectious diseases (see Further information).
*These are interesting initial observations; however, the overall patient benefit observed in these studies has remained relatively low.
most indicative of a long-term maintained effector T cell response. Starting from high levels, the virus titre usually strongly declines to levels that are undetectable in the blood within 4-8 weeks post infection and also decreases in infected organs (with the kidneys being a key exception as they continue to contain high titres) 14, 54 . Although the precise protective mechanisms under lying the decline in virus titre remain unclear, this observation suggests that the presence of an exhausted T cell phenotype does not preclude substantial virus control.
Infections that have a latent phase (for example, Epstein-Barr virus or cytomegalovirus (CMV) infections) differ in many respects from persisting LCMV clone 13 and HIV infections, but they are similar in that T cells become repetitively exposed to antigen. The mostly undetectable pathogen loads and the intermittent virus re-activation could mean that T cells are only exposed to low antigen levels in this type of infection. Nonetheless, T cells specific for antigens derived from latently persisting pathogens often increase over time -a process known as memory inflation 55 . T cells with such specificity often seem to be more activated than the memory T cells that are formed following the resolution of infection and they express killer cell lectin-like receptor subfamily G member 1 (KLRG1) 56 a marker that is frequently expressed by T cells in the acute infection phase 24 . Both of these observations indicate substantial antigen exposure over time, and yet the T cells retain a high functional capacity and strongly respond to virus re-activation [57] [58] [59] . Thus, repetitive exposure to pathogenderived antigen does not preclude or extinguish functional effector and memory T cell responses. Irrespective of the repetitive antigen exposure, T cells specific for latent infections lack or express only low levels of PD1, indicating that if there is PD1 expression, it might signal recent activation in these settings 60 . By contrast, persisting PD1 expression -as seen in LCMV clone 13, HIV or HCV infections -might correlate with the strength and magnitude of antigen stimulation, which is possibly lower in latent infections than in active chronic infections. This idea would be consistent with the concept that PD1 serves as a rheostat following strong T cell stimulation 27 . Moreover, several studies in active chronic infections have established links between the magnitude of T cell stimulation (or TCR avidity) and T cell fate. Accordingly, lower avidity or weakly stimulated T cells are prone to retain a normal phenotype, whereas higher avidity T cells acquire a chronic infection phenotype or they are deleted 61, 62 . This is somewhat reminiscent of the fact that T cells retain a rather normal effector phenotype in latent infections in which they might receive less TCR stimulation because of a lower degree of antigen exposure.
Differentiation and memory-like T cells
removed from an animal with chronic LCMV infection and re-exposed to antigen in the context of an acute LCMV infection 63 . Surprisingly, we observed that T cells that homo geneously expressed high levels of PD1 and low levels of cytokines could undergo robust re-expansion and form secondary effector T cells, and the transferred T cells even protected mice against a pathogen challenge 63 . Unexpectedly, even though the transferred cells were exposed to an acute infection, the vast majority of re-expanded T cells still displayed the exhausted T cell phenotype, continued to express low levels of cytokines and retained PD1 expression. Most interestingly, the exhausted phenotype was retained even when T cells from animals with chronic infection were challenged 4 weeks after they had been transferred into naive hosts (FIG. 1) . This outcome also implies the presence of T cells with memory-like properties within the transferred population 63 (a notion that is discussed in more detail below). This stability of the exhausted phenotype is supported by epigenetic studies showing that chronic LCMV clone 13 infection induces substantial and permanent demethylation in the promoter region of the gene encoding PD1 (Pdcd1). The demethylation was maintained in antigen-specific T cells long after the LCMV clone 13 virus load has dropped below detectable levels in the blood 64 . A lack of methylation in the PDCD1 promoter region has also been observed among antigenspecific CD8 + T cells from patients with HIV who have received long-term (>2 years) treatment with antiretroviral therapy or those from elite controllers 65 . The presence of PDCD1 demethylation in T cells from elite controllers of HIV infection further indicates a fixation of the epigenetic imprint in the PDCD1 locus. The view that T cells undergo a stable form of differentiation in chronic infections is also supported by studies showing that in spontaneously resolved HCV infection, CD8 + T cells retain an exhausted phenotype even after pathogen clearance 66 . What remains unknown, however, is when T cells undergo this differentiation. The incremental appearance of T cells with an exhausted phenotype led to the conclusion that prolonged exposure to antigen and inflammation causes a progressive acquisition of an exhausted phenotype 67 . Of note, this progression has only been described at the level of the entire population of antigenspecific T cells but there has not yet been a direct demonstration that a T cell, which at an early phase of a chronic infection displayed a normal phenotype, shows an exhausted phenotype at a later stage. It also needs to be acknowledged that a proportion of virus-specific T cells already show the typical monofunctional cytokine signature (that is, low-level IFNγ and no TNF production) in the early phase of an infection with LCMV clone 13, and that a considerable number of antigen-specific T cells display this phenotype in the early phase of acute infections 24 . This suggests that T cells displaying a key feature of exhaustion might be constitutively generated following activation in viral infections. Thus, T cells with a normal profile and T cells with an exhausted phenotype might be formed in parallel in the early phase of an infection and, depending on whether the infection remains acute or becomes chronic, a selective outgrowth occurs over time favouring one T cell phenotype over the other. This concept that the exhausted T cell phenotype could be generated at very early stages during infection and that these T cells progressively increasefrom an initial numerically under represented population to becoming the dominant population -would also be consistent with the aforementioned phenotypic stability of the exhausted phenotype.
Two recent papers have resolved the bulk population of antigen-specific T cells in acute infections into cells that originate from the same naive precursor (referred to as T cell families) 68, 69 . Interestingly, families of T cells that are initially underrepresented at the population level, and that have a substantially different phenotype and cytokine secretion profile from the average phenotype of the population, showed the highest secondary re-expansion potential. Thus, a higher re-expansion potential of underrepresented populations or families could effectively reshape the global phenotype of a T cell population following re-expansion. Such re modelling could also occur over time in chronic infection and this could result in a preferential outgrowth or selective survival of T cells that stably display an exhausted phenotype over T cells that show a conventional phenotype and which dominate the early phase of chronic infection.
Memory-like cells in chronic infections?
The survival of a proportion of exhausted T cells following transfer into antigen-free hosts, the ability of these T cells to undergo re-expansion, and the retention of a particular phenotype following re-expansion are hallmark features of memory T cells 63 . We therefore propose that a proportion of T cells in chronic infections form cells that behave like memory cells and that pass an exhausted phenotype to their progeny (FIG. 2) . Memory T cells that are formed after an acute infection ensure the rapid generation of large numbers of effector T cells upon pathogen re-exposure 5, 6, 70 . But why should cells with memory-like features be formed in chronic infections? These cells could constitute a reservoir to sustain a T cell response in chronic infections (FIG. 2) . In fact, it seems very unlikely that effector T cells which are formed, for instance, at the beginning of an HIV or HCV infection, may persist for months or years. It is more likely that these populations of antigen-specific T cells are maintained by memory-like cells that constantly replenish a pool of otherwise shortlived T cells. Such a replacement seems to occur in CMV infection 55 . A precursorprogeny relationship between subpopulations of T cells that differ in their expression of T-box transcription factors has also been shown in LCMV clone 13-infected mice 71 . This strongly suggests that long-term T cell responses in chronic infections are maintained by both functional diversification and by cells with memory-like features.
It has long been known that the elimination of CD4 + T cells increases viral load and decreases the number of pathogen-specific T cells in chronic LCMV infections 14, 54 . The precise mechanisms by which CD4 + T cells enhance the survival and effector function of CD8 + T cells remain unclear. We hypothesize that CD4 + T cells might fulfil a similar function in maintaining memory T cells in chronic infections as in acute infections 72 . Accordingly, the deteriorating T cell response in chronic infections that lack CD4 + T cells could be a consequence of losing the memory-like CD8 + T cells. Interestingly, a recent publication indicated that the impact of CD4 + T cells on CD8 + T cells in chronic infections is controlled by natural killer cells, which reduce the number of CD4 + T cells and consequently the number of CD8 + T cells 73 . We consider that memory-like T cells comprise only a very small proportion of the total population of antigen-specific T cells in chronic infections. This would be consistent with the observation of a rapid and more than 90% decline of engrafted T cells when T cells from LCMV clone 13-infected mice were transferred into naive mice in the absence of pathogen re-exposure 21, 25, 74 . We argue that this decline reflects only the loss of antigen-specific effector-like T cells but it does not preclude the selective survival of a few memory-like T cells. Besides, a decline of similar magnitude and kinetics occurs when day 8 effector T cells from acute infections are transferred Nature Reviews | Immunology + T cells, which indicated that virus had not been transferred. Both groups of secondary host mice were infected with an acute LCMV Armstrong infection 4 weeks after the transfer. The exhausted T cell phenotype that was acquired during the chronic infection could still be detected after the strong secondary expansion in an LCMV Armstrong infection 63 . IFNγ, interferon-γ; PD1, programmed cell death protein 1; TNF, tumour necrosis factor.
into naive mice and yet a low number of memory T cells survive 70 . Moreover, the notion that the bulk population of phenotypically exhausted T cells is more closely related to effector cells than to memory cells -on the basis of gene expression -supports the proposed model 75 . It also means that specific patterns of gene expression in memory-like T cells are most probably diluted by the numerical dominance of effector-like T cells in the total population of phenotypically exhausted T cells.
Functional control by inhibitory receptors
The goal of an immune response is to remove a pathogen. To achieve this, aggressive mechanisms are engaged at the risk of collateral tissue damage. We consider that the immune system adopts a different strategy in persisting infections that is driven by the need to balance pathogen control and tissue damage 22 . So far, the reduced ability of T cells to produce cytokines in chronic infections has been seen as a sign of deteriorating T cell function, but this phenotype could also simply represent an effector stage that is optimized to cause less inflammation and immunopathology than normal effector T cells. Such an adjustment, in combination with persisting expression of PD1, could be of vital importance in chronic infections 63, 64 . In strong support of this concept, it was recently shown that a high-dose virus infection, which induced an exhausted T cell phenotype, protected mice from immunopathology, whereas a lower dose that failed to induce exhaustion resulted in substantial pathology 73, 76 . Similarly, disrupting the von Hippel-Lindau tumour suppressor (VHL) gene causes overwhelming immunopathology by enforcing the cytotoxic activity of T cells in persisting infections 77 . PD1 signalling downmodulates T cell function in chronic infections but possibly also in acute infection, as PD1 expression is readily upregulated following T cell activation 24 . It also needs to be considered that it can be difficult to distinguish between PD1 expression that results from recent T cell stimulation and the maintained PD1 expression that is seen in the context of chronic infection. However, it remains unclear when and how the PD1 pathway is used in chronic infections. The sustained virus control in chronic infections argues against a constitutive PD1-PDL1 interaction. Perhaps, PD1 and other inhibitory pathways are primarily acting to prevent T cell responses in particular circumstances and those against tissues that are essential for the survival of the host. In line with this, differences in the expression of PD1 and its ligands in different tissues have been described 44 . Moreover, a crucial role of PD1-PDL1-mediated protection from endothelial cell damage and consequent circulation failure has recently been demonstrated 78 . Fixing PD1 expression in T cells in chronic infection would ensure that this axis remains accessible and is always ready to act as a potent control mechanism to limit T cell-mediated tissue damage 79 . Interestingly, tumour cells seem to benefit from this pathway and shield themselves against cytotoxic responses by expressing PD1 ligands [80] [81] [82] . An important question is why blocking PD1 in an established chronic LCMV clone 13 infection does not cause severe tissue damage 26, 27 . Although this needs to be investigated further, it could be a question of timing but also the efficacy of inhibition. Indeed, blocking the PD1-PDL1 interaction too early in LCMV clone 13 infections strongly increases the severity of immunopathology 78 . This could be seen as a further indication that in late-stage chronic infections, T cells undergo functional specialization and cause -even when they are unleashed from PD1-PDL1-mediated inhibition -much less immunopathology than more aggressive early-stage effector T cells.
Stable PD1 expression could also be very important to functionally control memory T cells that reside in tissues that are vulnerable to viral re-infection. The concept of tissue-resident memory CD8 + T cells is now established for several types of tissues and infections [83] [84] [85] [86] . Indeed, PD1 + CD8 + T cells have been found to be preferentially retained in the bone marrow, lymph nodes, kidneys and brain after chronic LCMV clone 13 infection 44 . Moreover, after vesicular stomatitis virus infection in mice, brain-resident effector memory CD8 + T cell populations were found to express high levels of PD1 and cytotoxic T lymphocyte antigen 4 (REF. 87 ). At the same time, these resident T cells often contain high levels of granzymes 88 . Thus, viral infections establish resident memory T cell populations in organs that are repeatedly targeted by similar pathogens to enable rapid pathogen control. The presence of PD1 expression on such resident memory T cells suggests a need to safeguard the cytotoxic and immunopathologycausing potential of these cells by controlling their effector function through the ligation of inhibitory receptors.
Perspectives
In contrast to the idea of a deteriorating T cell response in persisting infections, we support the existence of a prolonged T cell effector phase in chronic infection during Nature Reviews | Immunology This population shares key features with the conventional memory T cell population, constantly replaces the pool of otherwise short-lived effector T cells and stably transmits the exhausted phenotype to its descendants. This concept also suggests that the presence of a shortlived antigen-specific effector T cell population is a shared property of acute and chronic infections, with the difference that this population is rapidly lost in acute infection, whereas it is maintained by continuous replenishment over a long period (the prolonged effector phase) in chronic infections. In line with clinical observations, we suggest that this maintenance of the effector T cell pool may eventually decline over time (indicated by the arrows of decreasing thickness), ultimately resulting in a failure to sustain the effector response.
which considerable virus control is maintained by T cells that are well adapted and specialized to the conditions of chronic infections. We consider that these T cell responses are maintained through the formation of memory-like T cells that stably transmit an exhausted phenotype to otherwise short-lived effector T cells. In our opinion, such a prolonged effector phase much better reflects the pathophysiology of chronic infections. Instead of using the term exhausted, we therefore suggest using the term chronically activated effector T cells on the basis that these T cells retain a certain level of effector function. Nonetheless, more detailed studies are needed to compare their effector capacity with that of normal effector T cells. We anticipate that this prolonged effector phase only lasts for a certain period of time and that there is a final late stage at which a decline in the number of these chronically activated effector T cells and their corresponding memory-like counterparts occurs, ultimately leading to the loss of a functional T cell response (FIG. 2) . This ultimate demise of the T cell response is consistent with observations that T cell responses in chronic HCV, HIV or SIV infection clearly decline when analysed over long periods of time. The length of this prolonged effector phase -during which chronically activated effector T cells retain considerable control over virus and tumour burden -may vary between individuals and different types of infection. Presently, the main challenge is therefore to find ways to maintain T cells in this prolonged effector phase, to prevent their deterioration and to increase their function beyond what can be achieved by checkpoint blockade.
